Cambrooke Fully Funded

Ruffena Capital is pleased to announce that it acted as introducer and advisor to both Cambrooke Therapeutics. Inc.(Ayer, Mass, USA), a global therapeutic nutrition innovator, and Seventure Partners (Paris, France), a leading European Venture Capital Firm with €600m in assets under management, in the recent closing of Cambrooke's Series C investment round for an undisclosed amount. Seventure Partners was Lead Investor in this round.

Cambrooke offers the most advanced Medical Foods and functional foods for people with inborn errors of metabolism and intractable epilepsy. Its lead product for people with Phenylketonuria (PKU) represents the first significant advance in PKU since newborn screening for PKU started in the late 1960s.

Ruffena’s introduction of Seventure Partners enabled Cambrooke's existing main investor, Galen Partners (Stamford, Connecticut), a leading Healthcare Private Equity firm with $1 billion under management, as well as further co-investors from both Europe and the United States to participate in the round.

The completion allows Cambrooke to continue its European and global expansion as well as entry into other disease states. Seventure Partners invested out of its latest Health for Life Capital™ Fund, the first investment vehicle in the world to anticipate the microbiome revolution in the fields of health and nutrition.

Acting for Ruffena Capital: Dr Bernard Cummings

E: bernard.cummings@ruffena.com Mob: 07980054872.

To see all current Ruffena Capital opportunities visit our platform here.